scholarly journals Survival according to the site of bronchial microscopic residual disease after lung resection for non–small cell lung cancer

2009 ◽  
Vol 137 (3) ◽  
pp. 622-626 ◽  
Author(s):  
Stéphane Collaud ◽  
Massimo Bongiovanni ◽  
Jean–Claude Pache ◽  
Gérald Fioretta ◽  
John H. Robert
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Residual Disease ◽  
Lung Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Microscopic Residual Disease

Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery

2015 ◽  
Vol 99 (2) ◽  
pp. 406-413 ◽  
Author(s):  
Jacquelyn G. Hancock ◽  
Joshua E. Rosen ◽  
Alberto Antonicelli ◽  
Amy Moreno ◽  
Anthony W. Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adjuvant Treatment ◽  
Residual Disease ◽  
Lung Cancer Surgery ◽  
Small Cell ◽  
Cancer Surgery ◽  
Small Cell Lung ◽  
Microscopic Residual Disease

scholarly journals Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer

2013 ◽  
Vol 146 (2) ◽  
pp. 385-390.e2 ◽  
Author(s):  
Alessandro Brunelli ◽  
Michele Salati ◽  
Majed Refai ◽  
Francesco Xiumé ◽  
Rossana Berardi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Patient Centered ◽  
Aggregate Score

scholarly journals Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3112
Author(s):  
Elisa Gobbini ◽  
Aurélie Swalduz ◽  
Matteo Giaj Levra ◽  
Sandra Ortiz-Cuaran ◽  
Anne-Claire Toffart ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Relevance ◽  
Residual Disease ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Liquid Biopsies ◽  
Ctdna Analysis

Tumor genomic profiling has a dramatic impact on the selection of targeted treatment and for the identification of resistance mechanisms at the time of progression. Solid tissue biopsies are sometimes challenging, and liquid biopsies are used as a non-invasive alternative when tissue is limiting. The clinical relevance of tumor genotyping through analysis of ctDNA is now widely recognized at all steps of the clinical evaluation process in metastatic non-small cell lung cancer (NSCLC) patients. ctDNA analysis through liquid biopsy has recently gained increasing attention as well in the management of early and locally advanced, not oncogene-addicted, NSCLC. Its potential applications in early disease detection and the response evaluation to radical treatments are promising. The aim of this review is to summarize the landscape of liquid biopsies in clinical practice and also to provide an overview of the potential perspectives of development focusing on early detection and screening, the assessment of minimal residual disease, and its potential role in predicting response to immunotherapy. In addition to available studies demonstrating the clinical relevance of liquid biopsies, there is a need for standardization and well-designed clinical trials to demonstrate its clinical utility.

Sign in / Sign up

Export Citation Format

Share Document